Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GSK American Depositary Shares Representing 2 Ordinary Shares GSK

Consumer Cyclical
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with... see more

Recent & Breaking News (NYSE:GSK)

GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults

Business Wire March 14, 2023

The Year of the Tripledemic

TheNewsWire January 3, 2023

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

GlobeNewswire December 13, 2022

New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

Business Wire December 11, 2022

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

GlobeNewswire November 8, 2022

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

GlobeNewswire September 22, 2022

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

GlobeNewswire September 7, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

Newsfile September 1, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Newsfile August 17, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Accesswire August 16, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Newsfile August 16, 2022

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Accesswire August 15, 2022

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Newsfile August 15, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Business Wire August 15, 2022

Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc - GSK

Newsfile August 12, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Accesswire August 12, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm

Business Wire August 12, 2022

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

GlobeNewswire August 8, 2022

GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide

Business Wire August 8, 2022

GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis

Business Wire July 27, 2022